In conclusion, high KDM6A expression increases the HCC cell sensitivity in response to the RTKs inhibitor, that is, the KDM6A expression level may be a prognostic indicator for the efficacy of lenvatinib in HCC therapy. The gene discussed is KDM6A; the disease is hepatocellular carcinoma.